 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...27282930313233343536373839» |
- ||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Jun 3, 2019
P4, N=10, Active, not recruiting, Sponsor: Dr. Larry W. Moreland
Recruiting --> Active, not recruiting | N=90 --> 10
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Biomarker, Review, Journal: Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn's Disease-A Systematic Review and Gene Ontology Analysis. (Pubmed Central) - May 31, 2019
Our gene ontology analysis shows that these networks have roles in apoptotic signalling, response to oxidative stress and inflammation pathways. We conclude that a more systematic approach with genome-wide search of genomic and expression biomarkers in the same patients is needed in future studies.
- | Journal: Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists. (Pubmed Central) - May 31, 2019
There was consensus with use of 4 biologics - adalimumab (81%), certolizumab (80%), etanercept (83%), and infliximab (76%) - in planned pregnancies but uncertainty on when they should be discontinued and their use in unplanned pregnancies. This national survey shows consensus among rheumatologists on the use of some csDMARDs and biologics/small molecules in IA patients planning pregnancy but varied knowledge on when to discontinue and what to do in unplanned pregnancies.
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Observational data, Journal: A multicentre observational study comparing patient reported outcomes to assess reliability of swollen and tender joint assessments and response to certolizumab treatment as compared to clinician assessments in rheumatoid arthritis. (Pubmed Central) - May 30, 2019
There is a moderate to high level of agreement between clinicians and patient TJC and SJC assessments that suggest it may be a useful option in assessing joints and response in RA. Further evaluation of RA activity tools such as Disease Activity Score of 28 joints, Crohn Disease Activity Index or Simple Disease Activity Index utilizing patient assessments may be worth exploring.
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies. (Pubmed Central) - May 30, 2019
CZP e-Device development was guided by intended user feedback through HFS, ensuring the final design addressed patients' needs. In both validation studies, participants successfully performed all critical tasks, demonstrating safe and effective e-Device self-injections.
- | Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. (Pubmed Central) - May 29, 2019
Women with moderate to severe refractory IC/BPS were more likely to experience significant improvement in symptoms with certolizumab pegol compared with placebo therapy. Further investigation of certolizumab pegol for the treatment of IC/BPS is warranted with a larger, longer, multicenter, randomized, placebo-controlled trial.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease. (Pubmed Central) - May 26, 2019
Among TNFI users, certolizumab showed a 3.38-fold (95% CI, 2.25-5.09) increased risk vs infliximab, and subcutaneously administered TNFIs also exhibited a higher risk (HR, 1.34; 95% CI, 1.18-1.53) than intravenous TNFIs. TNFIs pose a higher risk of serious infection compared with immunomodulators in children and young adults with IBD, and this risk differs among individual TNFIs and routes of administration.
- | Clinical, Review, Journal: Recommendations for Initiating Systemic Therapy in Patients with Psoriasis. (Pubmed Central) - May 25, 2019
The authors discuss the barriers to use of systemic agents and highlight the central importance of each patient's perspective when assessing disease severity. Additionally, practical strategies for selecting and safely initiating systemic therapy to optimize the treatment of patients with psoriasis are identified.
- | Biomarker, New trial: Ultrasound Enthesitis Response in Psoriatic Arthritis (clinicaltrials.gov) - May 19, 2019
P, N=100, Recruiting, Sponsor: Belfast Health and Social Care Trust
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, P3 data, Journal, Combination therapy: Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study. (Pubmed Central) - May 17, 2019
Additionally, practical strategies for selecting and safely initiating systemic therapy to optimize the treatment of patients with psoriasis are identified. CZP in combination with MTX showed an acceptable safety profile, a rapid onset of response and sustained effects in reducing the signs and symptoms of RA and improving physical function in Chinese patients with RA and an inadequate response to MTX.
- | Clinical, Journal: Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. (Pubmed Central) - May 17, 2019
Monoclonal TNF-α inhibitors induce a remarkable decrease in the recurrence of AU during a long-term follow-up period and lead to a significant steroid sparing effect along with stabilisation of visual acuity. Concomitant treatment with cDMARDs represented the sole variable associated with treatment duration in the long-term.
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis. (Pubmed Central) - May 17, 2019
Concomitant treatment with cDMARDs represented the sole variable associated with treatment duration in the long-term. No abstract available
- | Clinical, Journal: Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. (Pubmed Central) - May 15, 2019
BFR can be achieved in some patients with RA after bDMARD discontinuation in clinical practice. Use of TNFi(mAb) or CTLA4-Ig, sustained remission, Boolean remission, and no glucocorticoid use at the time of bDMARD discontinuation are advantageous for achieving BFR.
- | Clinical, Journal: Elderly psoriatic patients under biological therapies: an Italian experience. (Pubmed Central) - May 13, 2019
In conclusion, the age alone should not limit our therapeutic options. Further observational study using multiple data sources is needed to evaluate long-term effectiveness and safety for elderly psoriatic patients.
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators. (Pubmed Central) - May 11, 2019
Further observational study using multiple data sources is needed to evaluate long-term effectiveness and safety for elderly psoriatic patients. Our study showed that TNF-alpha inhibition with CMZ promptly results in a rapid decline of serum Dkk-1 levels, alongside decreased bone resorption and increased bone formation.
- | Clinical, Journal, HEOR: Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis. (Pubmed Central) - May 6, 2019
Our study showed that TNF-alpha inhibition with CMZ promptly results in a rapid decline of serum Dkk-1 levels, alongside decreased bone resorption and increased bone formation. Patients with PsA who switched to another TNFi had lower total healthcare expenditures and longer persistence compared with patients who switched to a non-TNFi biologic.
- | Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Journal: The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors. (Pubmed Central) - Apr 30, 2019
TNF-α inhibitors are relatively resistant to freezing temperatures similar to storage conditions previously observed in patients' homes. However, almost half of the stressed product samples showed formation of particles in the submicron and micron size range.
- | Review, Journal: Biologics in SAPHO syndrome: A systematic review. (Pubmed Central) - Apr 26, 2019
In SAPHO patients not responding to conventional treatment, TNF blockers appear to be the first choice. In patients failing TNF blockers, IL-1 inhibitors and biologics targeting the IL-17/IL-23 axis could be used.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) - Apr 24, 2019
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
In patients failing TNF blockers, IL-1 inhibitors and biologics targeting the IL-17/IL-23 axis could be used. Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Apr 2019 --> Apr 2020
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Apr 20, 2019
P3, N=163, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Apr 2019 --> Apr 2020 Trial completion date: Jul 2021 --> Jan 2021 | Trial primary completion date: Apr 2021 --> Dec 2020
- | Journal, HEOR: Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. (Pubmed Central) - Apr 14, 2019
This analysis demonstrates that secukinumab 150 mg is the most cost-effective treatment option for biologic-naïve AS patients compared to certolizumab pegol, adalimumab, golimumab, etanercept and etanercept biosimilar, and infliximab and infliximab biosimilar for a lifetime horizon in Canada. Treatment with secukinumab translates into substantial benefits for patients and the healthcare system.
- | Clinical, Journal, Real-World Evidence: One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. (Pubmed Central) - Apr 11, 2019
Treatment with secukinumab translates into substantial benefits for patients and the healthcare system. After using PS matching to minimize channeling bias and compare patients with a similar likelihood of receiving CZP or other TNFi, the 1-year risk of SIEs, malignancies, and CVEs was not distinguishable between the two groups.
- | Clinical, Journal: First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. (Pubmed Central) - Apr 7, 2019
The medication persistence was different between biological drugs. The rigorous follow-up of patients, by a multidisciplinary team, is important to enable the development of strategies for the adequate use of such drugs.
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature. (Pubmed Central) - Apr 5, 2019
Moreover, we also present a literature review of the previously published cases with certolizumab-pegol induced psoriasiform eruption. Since all of these cases had Crohn's disease or rheumatoid arthritis as the underlying disease, this is the first case report of certolizumab-pegol induced psoriasiform eruption in a patient with ankylosing spondylitis, to the best of our knowledge.
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Preclinical, Journal: Ameliorative effect of certolizumab on experimentally induced acute necrotic pancreatitis in rats. (Pubmed Central) - Apr 5, 2019
Since all of these cases had Crohn's disease or rheumatoid arthritis as the underlying disease, this is the first case report of certolizumab-pegol induced psoriasiform eruption in a patient with ankylosing spondylitis, to the best of our knowledge. The results support the idea that certolizumab might be beneficial for the severity of AP.
- Composition and variation of gut microbiota in rheumatoid arthritis patients following different antirheumatic therapies () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_723;
Marked microbial shifts were identified in the GM between HC and AR patients, suggesting that the microbiota may play an important role in the clinical course of RA. Moreover, this is the first study describing the effects evoked by different bDMARDs on the GM structure of AR patients.
- ||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical: I switched to Humira and again it worked somewhat until it didn't. I then switched to Cimzia ... reacted to that. Currently on Stelara. So far no crazy reactions but sadly even while taking all of these I've had 19 surgeries and never achieved a true remission. (Twitter) - Apr 4, 2019
- || Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
UCB extends label for Cimzia to cover rare autoimmune condition https://t.co/iJ6Trih6UE #biotech @US_FDA (Twitter) - Apr 2, 2019
- | Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia https://t.co/W1m1FSLNuL #PinkSheet (Twitter) - Apr 1, 2019
- ||| Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
FDA event: Not sure that this will change my prescribing: FDA approves Cimzia for nonradiographic axial SpA. @RheumNow https://t.co/m2NSccq9ng (Twitter) - Mar 29, 2019
- || Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
FDA OKs Certolizumab for Nonradiographic Axial Spondyloarthritis https://t.co/XddNAiGwrn vía @medscape (Twitter) - Mar 29, 2019
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Journal: Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol. (Pubmed Central) - Mar 25, 2019
In our case, we are stressing on the mechanism of DITMA by a probable immune mediated and autoimmune process due to an antibody. Anti-drug antibodies and their immunological aspects are still unclear and awaiting to be elucidated.
- |||| Important to be aware of for anyone on an anti-TNF therapy #IBD including Remicade, Humira, CImzia, and Simponi. Added to anti-TNF labeling by the @US_FDA in 2011 https://t.co/Xx5tBHs5Qw (Twitter) - Mar 24, 2019
- | Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal, Real-world evidence: Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned. (Pubmed Central) - Mar 23, 2019
We describe the limitations of an EMR in our attempt to conduct a seemingly simple study aimed at validating variables identified in the PRECiSE 3, a 7-year open label safety and efficacy study of certolizumab pegol in Crohn's disease that identified clinical factors that predicted both short- and long-term efficacy...Significant challenges with reliable capture of key data elements were encountered, and overall a screen fail rate of 91.8% across all sites was seen. We describe these challenges and potential future directions to work together to advance accuracy and implementation of the use of EMRs in inflammatory bowel disease.
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Re: A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. (Pubmed Central) - Mar 23, 2019
We describe these challenges and potential future directions to work together to advance accuracy and implementation of the use of EMRs in inflammatory bowel disease. No abstract available
- | Clinical, Journal, Combination therapy: Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. (Pubmed Central) - Mar 20, 2019
...Against most targeted DMARDs, sarilumab 200 mg showed no statistically significant differences, except superiority to baricitinib 2 mg, tofacitinib and certolizumab on 24 week mTSS...TNFi-IR: Sarilumab 200 mg was similar to abatacept, golimumab, tocilizumab 4 mg and 8 mg/kg intravenously and rituximab on ACR20/50/70, superior to baricitinib 2 mg on ACR50 and DAS28<2.6 and to abatacept, golimumab, tocilizumab 4 mg/kg intravenously and rituximab on DAS28<2.6...Serious adverse events, including serious infections, appeared similar for sarilumab versus comparators. Results suggest that in csDMARD-IR and TNFi-IR (a smaller network), sarilumab+csDMARD had superior efficacy and similar safety versus placebo+csDMARDs and at least similar efficacy and safety versus other targeted DMARDs+csDMARDs.
- | Retrospective data, Journal: Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis. (Pubmed Central) - Mar 20, 2019
Similar rankings of efficacy and incremental cost per responder were observed in the analysis among biologic-naive patients. Adalimumab, golimumab, and infliximab were associated with higher efficacy and lower incremental costs per responder for both joint and skin responses in active PsA.
- || Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis (clinicaltrials.gov) - Mar 7, 2019
P2a, N=76, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Adalimumab, golimumab, and infliximab were associated with higher efficacy and lower incremental costs per responder for both joint and skin responses in active PsA. Recruiting --> Active, not recruiting
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Feb 11, 2019
P3, N=163, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Recruiting --> Active, not recruiting Trial completion date: May 2019 --> Jul 2021 | Trial primary completion date: Feb 2019 --> Apr 2021
- | Trial completion date: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Feb 4, 2019
P=N/A, N=50, Active, not recruiting, Sponsor: University of Maryland
Trial completion date: May 2019 --> Jul 2021 | Trial primary completion date: Feb 2019 --> Apr 2021 Trial completion date: Dec 2018 --> Jul 2019
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis (clinicaltrials.gov) - Jan 25, 2019
P2/3, N=149, Completed, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Dec 2018 --> Jul 2019 Active, not recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: PreCePRA: Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain (clinicaltrials.gov) - Jan 23, 2019
P3, N=156, Recruiting, Sponsor: University of Erlangen-N
Active, not recruiting --> Completed Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia (clinicaltrials.gov) - Jan 14, 2019
P=N/A, N=12500, Enrolling by invitation, Sponsor: UCB Pharma
Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Dec 2018 --> Aug 2019
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CIMPACT: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Jan 8, 2019
P3, N=559, Completed, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Dec 2018 --> Aug 2019 Active, not recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Trial primary completion date: RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) - Jan 8, 2019
P4, N=400, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Active, not recruiting --> Completed Trial primary completion date: Oct 2018 --> Oct 2020
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Dec 24, 2018
P4, N=812, Active, not recruiting, Sponsor: Karolinska Institutet
Trial primary completion date: Oct 2018 --> Oct 2020 Recruiting --> Active, not recruiting
- || Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis (clinicaltrials.gov) - Dec 14, 2018
P2a, N=60, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Recruiting --> Active, not recruiting Trial completion date: Sep 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: Study of Cimzia for the Treatment of Ulcerative Colitis (clinicaltrials.gov) - Dec 7, 2018
P2, N=25, Active, not recruiting, Sponsor: University of Washington
Trial completion date: Sep 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jun 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CIMPASI-1: An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Dec 4, 2018
P3, N=234, Completed, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- | Trial primary completion date: Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (clinicaltrials.gov) - Dec 4, 2018
P4, N=500, Recruiting, Sponsor: Karolinska Institutet
Active, not recruiting --> Completed Trial primary completion date: Mar 2019 --> Jun 2020